How cancer evades immune system detection and spreads
A research team led by the National Cancer Centre Singapore (NCCS) with members from Duke-NUS Medical School, KK Women and Children’s Hospital, A*STAR's Singapore Immunology Network (SIgN), the University of Southampton and the Alan Turing Institute, has discovered how cancer evades the immune system and metastasises in the body, and explores how to shut down this dangerous feature. (Source: World Pharma News)
Source: World Pharma News - April 11, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
New therapy harnesses patients & #039; blood cells to fight tumors
Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies and harsh chemotherapy drugs. (Source: World Pharma News)
Source: World Pharma News - April 10, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
New therapy harnesses patients' blood cells to fight tumors
Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies and harsh chemotherapy drugs. (Source: World Pharma News)
Source: World Pharma News - April 10, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Researchers leverage cell self-destruction to treat brain tumors
Glioblastoma is the most common type of brain tumor in adults. The disease is 100% fatal and there are no cures, making it the most aggressive type of cancer. Such a poor prognosis has motivated researchers and neurosurgeons to understand the biology of tumors with the goal of creating better therapies. (Source: World Pharma News)
Source: World Pharma News - April 7, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
CycPeptMPDB: A database aimed at promoting drug design using cyclic peptides
CycPeptMPDB, a novel database - created by Tokyo Tech researchers - focused on the membrane permeability of cyclic peptides, could accelerate the development of drugs based on these promising compounds. This database was created by gathering published information on thousands of cyclic peptides and organizing it neatly in an online-accessible platform. (Source: World Pharma News)
Source: World Pharma News - April 6, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
FDA accepts Pfizer's Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. (Source: World Pharma News)
Source: World Pharma News - April 5, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Tumor avatars to fight colorectal cancer
How to determine the most effective treatment for colon cancer? The response to chemotherapy varies greatly from one patient to another. A team from the UNIGE has developed a new method for testing different drugs, without going through the affected person’s body and without resorting to animal experiments. The researchers used organoids - miniature reproductions of organs and tissues - derived from patients and exposed to treatments. (Source: World Pharma News)
Source: World Pharma News - April 4, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Novo Nordisk Foundation to support crucial education of health professionals in India and East Africa with up to DKK 1bn (USD 140m)
The global shortage of qualified health professionals is an increasing challenge. According to the WHO, an additional 10 million health professionals will be needed by 2030. The demand is particularly acute in low- and middle-income countries, where health systems are already under immense pressure. With the launch of the Partnership for Education of Health Professionals (PEP), the Novo Nordisk Foundation takes a step towards reducing inequity in health by initially targeting the education of health professionals in underserved regions in India and East Africa. (Source: World Pharma News)
Source: World Pharma News - April 3, 2023 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news
Bayer Pharmaceuticals accelerates innovations for patients
At its annual Pharma Media Day 2023, Bayer presented the latest progress in the ongoing transformation of its pharmaceutical business focusing on accelerating innovative healthcare solutions for the benefits of patients and delivering long-term, sustainable business growth. (Source: World Pharma News)
Source: World Pharma News - March 31, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
AI predicts enzyme function better than leading tools
A new artificial intelligence tool can predict the functions of enzymes based on their amino acid sequences, even when the enzymes are unstudied or poorly understood. The researchers said the AI tool, dubbed CLEAN, outperforms the leading state-of-the-art tools in accuracy, reliability and sensitivity. Better understanding of enzymes and their functions would be a boon for research in genomics, chemistry, industrial materials, medicine, pharmaceuticals and more. (Source: World Pharma News)
Source: World Pharma News - March 30, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
FDA approves first over-the-counter naloxone nasal spray
Today, the U.S. Food and Drug Administration approved Narcan, 4 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription, use - the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose. (Source: World Pharma News)
Source: World Pharma News - March 29, 2023 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Candidate found to inhibit malignant melanoma growth
Malignant melanoma is a relatively aggressive type of skin cancer. When detected early, it is usually treatable by surgical resection only, but metastases develop often spreading to distant areas. Currently, tumor thickness and the presence of ulceration are some of the known prognostic factors used as indicators of malignant melanoma. Therefore, the discovery of valuable markers to assess the malignant potential of melanoma more accurately may be necessary to develop appropriate treatments. (Source: World Pharma News)
Source: World Pharma News - March 28, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
Novartis presented new data which underscore the transformational and sustained benefit of Zolgensma® (onasemnogene abeparvovec), an essential one-time gene therapy for the treatment of spinal muscular atrophy (SMA). Latest data from two Long-Term Follow-Up (LTFU) studies, LT-001 and LT-002, show the continued efficacy and durability of Zolgensma across a range of patient populations, with an overall benefit-risk profile that remains favorable. (Source: World Pharma News)
Source: World Pharma News - March 27, 2023 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
Researchers have developed a molecule that is, when administered nasally, extremely effective in preventing the disease caused by all known variants of the SARS-CoV-2 virus. The molecule can be a key tool in preparing for future pandemics, as it is aimed at preventing both the transmission and spread of the virus.
In laboratory animal studies, a molecule known as TriSb92, developed by researchers at the University of Helsinki, has been confirmed as affording effective protection against coronavirus infection. (Source: World Pharma News)
Source: World Pharma News - March 24, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
The 20th anniversary edition of the CPHI Pharma Awards is now open for entries, with three new categories created to reflect the surge of innovation sweeping the industry - from new methodologies to sustainability and philanthropic initiatives.
In the last year, pharma has continued its rapid rate of innovation embracing the speed of pandemic R&D, but added to this are new social goals that aim to improve the wider world as well as bottom lines and therapeutic/device options. (Source: World Pharma News)
Source: World Pharma News - March 23, 2023 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news
